GT-00X

GT-00X is an undisclosed, preclinical oncology biologic program from Glycotope that comprises antibodies directed against tumor‑specific glycan epitopes (“GlycoTargets”) and is being developed in formats including an antibody‑drug conjugate and a next‑generation bispecific antibody for the treatment of solid tumors.[1][2][7][8] By exploiting Glycotope’s tumor‑specific O‑glycan targets, GT-00X is intended to deliver potent cytotoxic or immune‑engaging payloads selectively to malignant cells while sparing normal tissues, positioning it as a targeted therapy platform for neoplasms.[1][2][7][8] Detailed target antigens, payloads, and specific indications have not been publicly disclosed beyond classification as a GlycoTarget‑directed ADC and bispecific antibody program in the preclinical stage.[1][7]